Mainz Biomed (MYNZ) said Thursday it partnered with Quest Diagnostics (DGX) to support the commercialization of its NextGen screening test for colorectal cancer.
Under the agreement, the company said Quest will provide clinical trial laboratory services for its clinical trial involving about 15,000 participants across 150 US sites, adding that the study will generate data for FDA validation of the NextGen test.
The medical test maker also said it would offer Quest semi-exclusive rights to provide testing services using the ColoAlert kit for 18 months, contingent on FDA approval.
ColoAlert test is a stool-based test to detect colorectal cancer tumor DNA to help identify colorectal cancer in its early stages.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。